论文部分内容阅读
目的 观察评价血脂康对原发性高胆固醇血症患者的疗效及安全性。方法 将 6 4例高胆固醇血症患者随机分为试验组 (口服血脂康 0 6g ,每日 2次 )及对照组 (口服国产洛伐他汀 2 0mg晚饭后 1次 ) ,观察 8周疗效。结果 与治疗前相比 ,试验组服药后 8周血清总胆固醇、甘油三酯、低密度脂蛋白胆固醇分别下降2 3 8%、2 8 5 %、30 5 % ,高密度脂蛋白胆固醇则上升 13 5 % (P <0 0 1) ;以上各项总有效率分别为 90 3%、70 1%、6 1 3%、87 1%。血脂康调脂疗效与洛伐他汀相似 (P >0 0 5 ) ,且无明显毒副作用。结论 血脂康对原发性高胆固醇血症患者疗效明显 ,是一种安全有效的调脂药
Objective To observe and evaluate the efficacy and safety of Xuezhikang in patients with primary hypercholesterolemia. Methods Sixty-four patients with hypercholesterolemia were randomly divided into experimental group (oral Xuezhikang 6g, twice daily) and control group (oral domestic lovastatin 20mg once after dinner). The curative effect was observed after 8 weeks. Results Compared with those before treatment, the levels of serum total cholesterol, triglyceride and low density lipoprotein cholesterol decreased by 23.8%, 28.5% and 30.5%, while those of high-density lipoprotein cholesterol increased by 13% 5% (P <0.01). The above total effective rates were 90.3%, 70.1%, 61.3%, 87.1% respectively. Xuezhikang lipid-lowering effect and lovastatin similar (P> 0 05), and no obvious side effects. Conclusion Xuezhikang obvious effect on patients with primary hypercholesterolemia is a safe and effective lipid-lowering drugs